Recurrence Rates in Ductal Carcinoma in Situ Declining Over Time

Share this content:
Patients with ductal carcinoma in situ have been experiencing a lower rate of recurrence over time.
Patients with ductal carcinoma in situ have been experiencing a lower rate of recurrence over time.

Patients with ductal carcinoma in situ (DCIS) have been experiencing a lower rate of recurrence over time, according to an abstract presented at the American Society of Clinical Oncology's 2015 Breast Cancer Symposium in San Francisco, CA.1

Investigators examined recurrence rates after breast-conserving surgery (BCS) for DCIS over 3 decades at one institution. It prospectively maintained a database of patients with DCIS undergoing BCS. Patients treated between 1978 and 2010 were included in the study.

Results showed that among the 2,996 cases that were observed, there was a 12% recurrence rate. Median follow-up for patients without recurrence was 75 months (range 0 to 30 years). A total of 732 patients were followed-up for 10 years or longer.

The 5-year recurrence rate for patients treated between 1978 and 1998 was 13.6% compared with 6.6% for patients treated between 1999 and 2010 (HR: 0.62; P=0.0001).

RELATED: In Invasive Ductal Carcinoma, Paget's Disease Associated With Increased Risk of Metastasis

Following stratification by radiation use, and adjustment for 7 other factors, the decrease in recurrence rates was limited to those who did not receive radiation (HR: 0.62; P=0.003). There was no decline in recurrence rates among those who received radiation therapy (HR:1.13; P=.06).

Increases in screen-detection, negative margins and use of adjuvant therapy only partially explain the results. It may be due to improvements in radiologic detection and pathologic assessment. In light of the recent increase in the use of mastectomy, these results are particularly important for patient education.

Reference

  1. Van Zee K, Subhedar P, Ocese C, et al. Recurrence rates for ductal carcinoma in situ: analysis of 2,996 patients treated with breast-conserving surgery over 30 years. Abstract presented at the American Society of Oncology's 2015 Breast Cancer Symposium; September 25-27, 2015; San Francisco, CA. http://abstracts.asco.org/163/AbstView_163_155076.html. Accessed September 30, 2015. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters